We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
REFIXIA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
REFIXIA
Date registered
Evaluation commenced
Decision date
Approval time
192 working days (255)
Active ingredients
nonacog beta pegol
Registration type
NCE/NBE
Indication
REFIXIA (solution for injection) is indicated for the treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia B (congenital factor IX deficiency).